An intrauterine system (IUS), also known as an intrauterine device (IUD), is a small, T-shaped piece of plastic inserted into the uterus to help prevent pregnancy. Many people are confused about how ...

Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine ...

Data showing that Liletta (Allergan/Medicines360), a 52-mg levonorgestrel-releasing intrauterine device (IUD), was highly effective in preventing pregnancy out to 5 years in slim to obese American ...

Patients who used copper intrauterine devices (Cu IUD) were found to have a lower risk of high-grade cervical neoplasms (cervical cancer) compared to users of the levonorgestrel-releasing intrauterine ...

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...

Lower-dose IUDs were associated with an increased risk for ectopic pregnancy compared with higher-dose systems, according to a retrospective cohort study published in Obstetrics & Gynecology. Overall, ...

Turok, MD, MPH and Mitchell Creinin, MD Honored at the Society for Family Planning Annual Meeting In Pittsburgh ROSWELL, Ga., Oct. 27, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela ...

Women younger than 50 who used a levonorgestrel-releasing intrauterine device (IUD) had a significantly higher risk of breast cancer as compared with women who did not use hormonal contraceptives, a ...

Mepivacaine instillation significantly reduced pain during intrauterine device (IUD) placement in nulliparous women. More than 90% of women in the intervention group reported tolerable pain compared ...

To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world through an online application process, paying special attention to growing fields—such as ...

Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced that the journal Contraception has awarded the publication of Phase 3 data of MIUDELLA® (copper intrauterine system) one ...

The MarketWatch News Department was not involved in the creation of this content. ROSWELL, Ga., Oct. 15, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today ...